Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
Oncotelic Therapeutics (OTLC) announced the expansion of its Sapu003 Phase 1b clinical program beyond Australia into Europe. The company appointed Global Clinical Trials (GCT) as the lead contract research organization to support the international execution of Study SP-03-B101.
Key figures
- Drug Name
- Sapu003 (Everolimus for Injection)
- Phase Of Trial
- Phase 1b
- Study id
- SP-03-B101
- Gmp bio interest
- 45%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.